biovox.be
White Papers - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/white-papers
BioVox - Life sciences Breakthroughs. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Vision / opinion / people. Cancer Immunotherapy - expected April/May 2017. We are currently developing a White Paper on Cancer Immunotherapy, showcasing innovators and world leaders in this exciting field. This in-depth publication provides life sciences stakeholders wit. Vision / opinion / people. Please fill out all fields. ABOUT BIOVOX - Sharing Life Sciences Innovations.
biovox.be
Flanders Innovation and Enterpreneurship hands out over 500 million euros - Insights - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/insights/detail/flanders-innovation-and-enterpreneurship-hands-out-over-500-million-euros
BioVox - Life sciences Breakthroughs. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Inside a life sciences fund: V-Bio Ventures. V-Bio Ventures, the new Belgian fund for life sciences startups, is currently being managed by Christina Takke and Willem Broekaert. They both hav. Biotech through the eyes of a financial analyst. Belgium’s investment market amongst the best in Europe. Vision / opinion / people. Tuesday 13 December 2016. In the category Interviews.
biovox.be
VC Views - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/vc-views
BioVox - Life sciences Breakthroughs. Science needs to be backed by a solid business model to be successful beyond the lab. BioVox teamed up with the venture capital fund V-Bio Ventures to bring you their unique view on life science innovations. VC Views, powered by V-Bio Ventures. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Vision / opinion / people. V-Bio feature: Mosquito Wars. V-Bio Ventures spends big money in life sciences. V-Bio Ventures, the new Be...
biovox.be
News - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/news
BioVox - Life sciences Breakthroughs. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Vision / opinion / people. Cell therapy for Crohn's disease gets FDA boost to enter US market. TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has r. Merck releases compelling data on Ablynx-developed psoriasis nanobody. In a press rel...
biovox.be
Insights - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/insights
BioVox - Life sciences Breakthroughs. The insight section provides you with in-depth information, state-of-the-arts, user experiences and updates on interesting life sciences ventures. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Vision / opinion / people. DuPont Pioneer’s next generation of waxy corn shows the green side of CRISPR-Cas9. Interspecies chimeras: One embryo, two species. PharmaFluidics Micro-Chips: Not for Computers. Using the gut bacterium Ak...
biovox.be
Confo Therapeutics: Drugging the Undruggable - VC Views - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/vc-views/detail/confo-therapeutics-drugging-the-undruggable
BioVox - Life sciences Breakthroughs. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Prof Carmeliet as Chief Scientific Strategy Advisor at Oncurious. Oncurious NV, an oncology company focused on the development of innovative medicines for the treatment of pediatric tumors, today announces the ap. Vision / opinion / people. Confo Therapeutics: Drugging the Undruggable. Tuesday 13 December 2016. In the category VC Views. With the tags startup. Currently, GPCR-...
biovox.be
Biowin presents the SMART project - Insights - BioVox - Life sciences Breakthroughs
http://www.biovox.be/en/insights/detail/biowin-presents-the-smart-project
BioVox - Life sciences Breakthroughs. Join our 20.000 subscribers and receive the newsletter for free! Please fill out all fields. Celyad Announces Registration of the first patient in the Belgian THINK trial. Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy. Argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis. ABLYNX INITIATES PHASE IIb STUDY OF INHALED ANTI-RSV NANOBODY. Vision / opinion / people. Biowin presents the SMART project. Was also involv...